title: An atypical presentation of ACAD9 deficiency: Diagnosis by whole exome sequencing broadens the phenotypic spectrum and alters treatment approach.
abstract: Acyl-CoA dehydrogenase 9 (ACAD9), linked to chromosome 3q21.3, is one of a family of multimeric mitochondrial flavoenzymes that catalyze the degradation of fatty acyl-CoA from the carnitine shuttle via β-oxidation (He et al. 2007). ACAD9, specifically, is implicated in the processing of palmitoyl-CoA and long-chain unsaturated substrates, but unlike other acyl-CoA dehydrogenases (ACADs), it has a significant role in mitochondrial complex I assembly (Nouws et al. 2010 & 2014). Mutations in this enzyme typically cause mitochondrial complex I deficiency, as well as a mild defect in long chain fatty acid metabolism (Haack et al. 2010, Kirby et al. 2004, Mcfarland et al. 2003, Nouws et al. 2010 & 2014). The clinical phenotype of ACAD9 deficiency and the associated mitochondrial complex I deficiency reflect this unique duality, and symptoms are variable in severity and onset. Patients classically present with cardiac dysfunction due to hypertrophic cardiomyopathy. Other common features include Leigh syndrome, macrocephaly, and liver disease (Robinson et al. 1998). We report the case of an 11-month old girl presenting with microcephaly, dystonia, and lactic acidosis, concerning for a mitochondrial disorder, but atypical for ACAD9 deficiency. Muscle biopsy showed mitochondrial proliferation, but normal mitochondrial complex I activity. The diagnosis of ACAD9 deficiency was not initially considered, due both to these findings and to her atypical presentation. Biochemical assay for ACAD9 deficiency is not clinically available. Family trio-based whole exome sequencing (WES) identified 2 compound heterozygous mutations in the ACAD9 gene. This discovery led to optimized treatment of her mitochondrial dysfunction, and supplementation with riboflavin, resulting in clinical improvement. There have been fewer than 25 reported cases of ACAD9 deficiency in the literature to date. We review these and compare them to the unique features of our patient. ACAD9 deficiency should be considered in the differential diagnosis of patients with lactic acidosis, seizures, and other symptoms of mitochondrial disease, including those with normal mitochondrial enzyme activities. This case demonstrates the utility of WES, in conjunction with biochemical testing, for the appropriate diagnosis and treatment of disorders of energy metabolism.
authors.affiliation: Phoenix Children's Hospital, Division of Genetics and Metabolism, United States; Phoenix Children's Hospital Rosenberg Children's Medical Building 1920 E. Cambridge Ave Ste 301 Phoenix, AZ 85006, United States.
authors.forename: H K
authors.initials: HK
authors.lastname: Aintablian
authors.affiliation: Tgen's Center for Rare Childhood Disorders (C4RCD), United States; Tgen 445 N 5th St, Phoenix, AZ 85004, United States.
authors.forename: V
authors.initials: V
authors.lastname: Narayanan
authors.affiliation: Tgen's Center for Rare Childhood Disorders (C4RCD), United States; Tgen 445 N 5th St, Phoenix, AZ 85004, United States.
authors.forename: N
authors.initials: N
authors.lastname: Belnap
authors.affiliation: Tgen's Center for Rare Childhood Disorders (C4RCD), United States; Tgen 445 N 5th St, Phoenix, AZ 85004, United States.
authors.forename: K
authors.initials: K
authors.lastname: Ramsey
authors.affiliation: Phoenix Children's Hospital, Division of Genetics and Metabolism, United States; Phoenix Children's Hospital Rosenberg Children's Medical Building 1920 E. Cambridge Ave Ste 301 Phoenix, AZ 85006, United States.
authors.forename: T A
authors.initials: TA
authors.lastname: Grebe